Quest Diagnostics Incorporated
DGX · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.66 | 0.65 | -42.26 | -12.63 |
| FCF Yield | 1.96% | 2.17% | 1.05% | 2.04% |
| EV / EBITDA | 49.90 | 43.93 | 51.56 | 45.60 |
| Quality | ||||
| ROIC | 2.02% | 2.26% | 1.90% | 1.90% |
| Gross Margin | 33.70% | 34.15% | 32.54% | 32.74% |
| Cash Conversion Ratio | 2.17 | 1.84 | 1.34 | 2.09 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.28% | 3.51% | 1.89% | -0.04% |
| Free Cash Flow Growth | -3.90% | 121.32% | -42.23% | 36.40% |
| Safety | ||||
| Net Debt / EBITDA | 10.88 | 10.18 | 13.08 | 12.58 |
| Interest Coverage | 5.59 | 6.35 | 4.81 | 5.01 |
| Efficiency | ||||
| Inventory Turnover | 10.04 | 9.72 | 9.47 | 9.38 |
| Cash Conversion Cycle | -14.74 | -9.29 | -5.58 | -16.53 |